During a talk at the recent Jefferies Global Healthcare Conference, Cogent CEO Andy Robbins said Blueprint Medicines’ Ayvakit ...

Blueprint Medicines stock was soaring Monday after French drugmaker Sanofi said it had agreed to buy the biotech company for $9.5 billion. Shares in Blueprint jumped 26% to $127.77 in early trading.

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

The acquisition includes a rare immunology disease medicine and an advanced and early-stage immunology pipeline.

The deal includes a drug approved in the U.S. and the EU for systemic mastocytosis, a rare immunology disease, as well as an early-stage immunology pipeline, the companies said.

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi acquires Blueprint Medicines Corporation for $9.1bn, gaining revenue-driving Aykavit and pipeline drug BLU-808 ...

Blueprint Medicines Corp. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a cyclin dependent kinase 2 ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

Sanofi to acquire Blueprint Medicines for up to $9.5B to expand its rare immunological disease portfolio, including an FDA-approved treatment.

Sanofi SAN-0.71%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC-0.05%decrease; red down pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...